Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Camurati-Engelmann Syndrome × ascrinvacumab × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Carcinoma, Transitional Cell 1 Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 1 enzalutamide 1 ascrinvacumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01620970 2021-05-14

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡